Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Difelikefalin QTc Study in Healthy Subjects
NCT04019574Phase 1Completed
- Sponsor
- Cara Therapeutics, Inc.
- Start
- Jun 2019
- Primary completion
- Oct 2019
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of difelikefalin in chronic kidney disease (CKD) (4 arms), sponsored by Cara Therapeutics, Inc. Primary endpoint: QTc change from baseline at Day 1. Started Jun 2019; status: completed.
02
Drugs
difelikefalin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT04019574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04019574.